| scholarly article | Q13442814 |
| P50 | author | Petra Muus | Q87993081 |
| Stefan Suciu | Q99568574 | ||
| Gert J Ossenkoppele | Q114428018 | ||
| P2093 | author name string | Frédéric Baron | |
| Theo de Witte | |||
| Dominik Selleslag | |||
| Sergio Amadori | |||
| Antoine Thyss | |||
| Claudio Denzlinger | |||
| Heinz Zwierzina | |||
| Karel Indrak | |||
| Michel Delforge | |||
| P2860 | cites work | Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 |
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 | ||
| Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. | Q33376783 | ||
| Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept | Q33828803 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study | Q34098328 | ||
| NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs) | Q34560200 | ||
| A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data | Q36602827 | ||
| Remicade as TNF suppressor in patients with myelodysplastic syndromes. | Q40482604 | ||
| Report of an international working group to standardize response criteria for myelodysplastic syndromes. | Q40737646 | ||
| Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes | Q43883722 | ||
| Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. | Q53217119 | ||
| Measurement of serum cytokine levels in patients with myelodysplastic syndromes | Q67802666 | ||
| Interferon‐γ and tumor necrosis factor‐α suppress both early and late stages of hematopoiesis and induce programmed cell death | Q71825079 | ||
| Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes | Q72344921 | ||
| Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin | Q72719183 | ||
| Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome | Q73834010 | ||
| Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) | Q74346540 | ||
| A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome | Q77476802 | ||
| Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study | Q77628536 | ||
| Myelodysplastic syndromes | Q82442488 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| myelodysplastic syndrome | Q954625 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 529-533 | |
| P577 | publication date | 2011-11-18 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group | |
| P478 | volume | 97 |
| Q38259434 | A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases |
| Q89208469 | Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes |
| Q33751652 | Evidence of selective reporting bias in hematology journals: A systematic review |
| Q91620661 | Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes |
| Q36193594 | Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases |
| Q47547344 | Infliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement: A case report |
| Q43235077 | Infliximab therapy in hematologic malignancies: handle with care. |
| Q38687894 | New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities |
| Q92798584 | Remicade® (infliximab): 20 years of contributions to science and medicine |
| Q46488130 | Reply to “Infliximab therapy in hematologic malignancies: handle with care” 2012;97(8):e26. |
| Q58777077 | Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia |
Search more.